Skin and Metabolic Health: What Your Skin Reveals About Disease

When a patient schedules an appointment for a rash, a patch of hair loss, or a painful nodule, they're focused on one thing: their skin. But as a dermatologist who has spent decades at the intersection of clinical practice and academic medicine, I've come to understand something that changes the way I approach every single patient encounter. The skin is the body's largest organ, and it rarely suffers in isolation. What appears on the surface is often a window, sometimes the very first window, into what is happening metabolically and hormonally beneath it.

This is the philosophy that guides my practice at Bordone Dermatology. When you come to me with a skin concern, I'm not just examining the lesion or scalp condition in front of me. I'm asking: what is the skin telling me about the rest of this person's body? And I'm ordering labs, thoughtfully, purposefully, because what the skin reveals often predates what standard screening tests will catch.

Why the Skin Speaks Before the Lab Does

Most patients assume that metabolic disease gets detected through routine bloodwork: a high HbA1c, a troublesome cholesterol panel, liver enzyme abnormalities, or elevated blood pressure. These are indeed the hallmarks of established metabolic disease. But the critical word is "established." These abnormalities tend to emerge in the more advanced stages of insulin resistance and metabolic syndrome. By the time your A1c is in the diabetic range, the metabolic disruption driving it has typically been present for years.

The skin, by contrast, responds earlier. Acanthosis nigricans (that velvety, darkened thickening of skin in the folds of the neck, axillae, and groin) has been shown to be a reliable early marker for metabolic syndrome, and its presence is tightly linked to insulin resistance and hyperinsulinemia (Medscape: Acanthosis Nigricans). For many patients, the identification of these dark patches on the skin may be the first indication that type 2 diabetes is in the early stages of development. This is a diagnosis a dermatologist is uniquely positioned to make, and act on.

The same logic extends far beyond acanthosis nigricans. Inflammatory skin diseases, hair disorders, and even certain autoimmune conditions of the skin are now understood to have deep metabolic roots. Recognizing this connection isn't just intellectually interesting, it can change the trajectory of a patient's systemic health.

Common Skin Findings and Their Metabolic Implications

Psoriasis and Obesity: A Bidirectional, Inflammatory Relationship

Psoriasis is one of the most well-studied examples of the metabolic-inflammatory link. It is an inflammatory skin disease affecting 2 to 4% of the world population. Adipose tissue, especially visceral fat, secretes bioactive products called adipokines, and the co-existence of psoriasis and obesity is at least in part attributed to their downstream inflammatory effects.

The numbers are striking. A systematic review and meta-analysis of 16 observational studies involving 2.1 million participants found a pooled odds ratio of 1.66 for obesity among patients with psoriasis compared to those without, and the association was even stronger in severe psoriasis (Armstrong et al., Nutrition & Diabetes, 2012). More recent prospective data paint an even starker picture: a dose-response meta-analysis found a 2 to 4-fold increase in psoriasis risk among those at the high end of adiposity measures compared to lean individuals (Huang et al., European Journal of Epidemiology, 2018).

What drives this connection? Activated macrophages in adipose tissue stimulate adipocytes to secrete inflammatory mediators such as TNF-α, IL-1, IL-6, and IL-8, the very cytokines implicated in psoriatic pathogenesis. Leptin is elevated in psoriasis patients while adiponectin, an anti-inflammatory adipokine, is decreased. In other words, excess fat tissue actively promotes and sustains the inflammatory environment that drives psoriatic disease.

This relationship has real treatment implications. Obese psoriasis patients respond less well to both conventional and biologic therapies, and psoriasis is significantly associated with diabetes mellitus, hypertension, and hyperlipidemia, a full metabolic constellation that demands evaluation beyond the skin (Choudhary et al., PubMed, 2024).

Hidradenitis Suppurativa: Where Obesity Is the Single Biggest Modifiable Risk Factor

If psoriasis illustrates the metabolic-inflammatory connection in skin disease broadly, hidradenitis suppurativa (HS) makes the case most urgently. HS is a chronic, painful inflammatory disease of the hair follicle, causing nodules, abscesses, draining tracts, and scarring in the axillae, groin, and other intertriginous areas. It is debilitating, undertreated, and deeply intertwined with metabolic health.

A systematic review and meta-analysis of 23 studies involving nearly 30 million patients found a significant association between HS and obesity, with a pooled odds ratio of 2.48, meaning individuals with higher body weight were approximately two and a half times more likely to develop HS. Obesity is not just a comorbidity in HS; it is the single largest modifiable risk factor for the disease (Elzawawi et al., International Wound Journal, 2024).

The metabolic picture in HS goes even deeper. Being metabolically unhealthy in addition to being overweight or obese further increases HS risk, and increased insulin resistance (as measured by HOMA-IR) is associated with worse disease severity. Critically, this relationship holds even in patients who are lean (Morin et al., PMC, 2023). This is precisely why I evaluate metabolic markers in every HS patient: the metabolic disease is feeding into the skin disease, and treating only the skin is an incomplete intervention.

The association of HS with metabolic syndrome (including diabetes, dyslipidemia, and obesity) has been consistently identified in controlled studies and is not limited to older or more severe patients (Kokolakis et al., PubMed, 2018). If you carry an HS diagnosis, a thorough metabolic workup is not optional. It is essential.

Alopecia Areata and Vitiligo: When the Immune System Turns on the Skin

Not all inflammatory skin diseases follow the same metabolic pathway. Alopecia areata and vitiligo occupy a different immunological category: they are autoimmune diseases characterized by loss of immune privilege, the specialized protective mechanism that normally shields certain tissues (like hair follicles and pigment-producing melanocytes) from immune attack.

The loss of immune privilege within hair follicles and the subsequent immune dysregulation are central to the development of alopecia areata (StatPearls: Alopecia Areata). In vitiligo, a parallel mechanism destroys melanocytes. Both diseases share a common dependence on IFN-γ-driven immune signaling pathways (Rashighi & Harris, Current Opinion, 2016).

Does metabolic health influence these immune privilege diseases? The evidence suggests yes, though the relationship is more nuanced than with psoriasis or HS. Obesity, reduced gut microbiome diversity, aberrant cortisol responses to chronic stress, and low serum vitamin D have all been proposed as inflammatory bridges that erode the immune privilege protecting hair follicles. The metabolic connection in alopecia areata is still being actively characterized, and the relationship is not as quantitatively dramatic as in HS or psoriasis, but the clinical implication is clear: patients presenting with these autoimmune hair and pigment disorders deserve a thoughtful review of their metabolic and immune health.

Hair Loss and Metabolic Health: The Hormonal Dimension

For my patients presenting with hair loss, metabolic evaluation is always part of the clinical workup, because the evidence for metabolic drivers of hair thinning is substantial and often overlooked.

The most common form of hair loss in both men and women is androgenetic alopecia (AGA), which is androgen-driven thinning in genetically predisposed individuals. Insulin resistance plays a pathogenetic role in the miniaturization of hair follicles: vasoactive substances associated with endothelial dysfunction in insulin resistance lead to microcirculatory disturbance and perifollicular vasoconstriction, literally strangling the blood supply to hair follicles (Bakry et al., Indian Dermatology Online J, 2014).

The hormonal interplay runs deeper still. Insulin resistance and the resulting insulin excess increase local androgen production and the peripheral conversion of testosterone to dihydrotestosterone (DHT), its more potent form, which in turn drives follicular miniaturization (El-Samahy et al., JCAD, 2020). This is a critical point for women in particular: as estrogen levels fall (with menopause, hysterectomy, or certain hormonal therapies) the relative dominance of androgens increases. Declining estrogen amplifies the hair follicle's sensitivity to insulin-driven androgen excess, creating a compounding effect that many women experience as sudden or accelerating hair loss in midlife.

Androgenetic alopecia can be considered an early clinical marker of metabolic syndrome, and it is now recommended that patients with AGA receive thorough evaluation for metabolic risk, not just treatment of the hair loss itself (Malkud, Dermatology & Aesthetic Research, 2018).

What I Look For, and Why Standard Screening Falls Short

The conventional approach to metabolic disease detection relies on markers that typically become abnormal only after significant systemic dysfunction has already set in. HbA1c crosses the diagnostic threshold for diabetes after years of insulin resistance that may never have triggered a flag on a standard panel. Abnormal cholesterol, liver enzymes, and hypertension all tend to present in the later stages of the metabolic continuum.

Skin changes, by contrast, appear earlier. A patient sitting in my exam chair with new-onset psoriasis, worsening HS, or accelerating hair thinning may have no diagnosis outside of dermatology, but may be years into a metabolic process that a dermatologist is uniquely positioned to identify and oftentimes treat, or refer appropriately. Patients don't typically connect a skin condition to a systemic disease. That connection is our job to make.

Lab Panel for Inflammatory Skin and Hair Disorders

The labs I order vary by presentation, but for patients with inflammatory skin disease or hair loss, my evaluation commonly includes:

• Fasting insulin and glucose / HOMA-IR: to detect insulin resistance before A1c becomes abnormal
• HbA1c and fasting glucose: standard diabetes screening
• Comprehensive lipid panel (including triglycerides and HDL): key components of metabolic syndrome
• Liver enzymes and GGT: metabolic-associated fatty liver disease is common in this population
• Thyroid function (TSH, free T3/T4): thyroid dysfunction is a frequent contributor to hair loss and inflammatory flares
• Sex hormones (total and free testosterone, DHEA-S, estradiol, SHBG): essential for understanding androgenic hair loss, especially in women
• Vitamin D: deficiency is prevalent in both obesity and autoimmune skin disease
• Ferritin and CBC: iron deficiency is a common and underrecognized driver of hair shedding

A Different Kind of Dermatologist

Dermatology has long been perceived as a specialty of surface, of what is seen, not what is hidden. But the science increasingly tells a different story. The skin is an endocrine organ, an immune organ, and a metabolic organ. It responds to hormones, to inflammation, to oxidative stress, and to the downstream effects of insulin resistance with remarkable sensitivity, often before any other organ reveals that something is wrong.

At Bordone Dermatology, I approach every patient as a whole person. A new diagnosis of HS is an opportunity to prevent or reverse metabolic disease. A patient with progressive hair loss may be living with unrecognized insulin resistance. Psoriasis flaring despite treatment may signal that the adipose-driven inflammation fueling it has never been addressed.

You deserve a dermatologist who looks deeper. One who reads your skin not just as a surface, but as a story, and who has the training and the commitment to help you understand what that story means.